NHLBI Regional Innovation Conference
Boston, MA
May 8, 2014

Merck Research Laboratories
33 Avenue Louis Pasteur
Boston, MA

HOSTS AND SPONSORS
Agenda

9:00am  Welcome remarks and NHLBI presentation

9:30am  Company presentations
- Thermomedical
- Progenra, Inc.
- Pulmokine, Inc.

10:15am Refreshments and partnering

10:45am MassBio/Health Advances presentation

11:00am Company presentations
- DeclImmun Therapeutics
- Giner, Inc.
- TheraSource, LLC
- PinMed, Inc.

12:00pm Lunch and partnering

1:00pm  NCAI & Boston Biomedical Innovation Center presentation

1:40pm  Company presentations
- DVX, LLC
- Prolong Pharmaceuticals

2:10pm  Partnering break

2:40pm  Investor perspective panel

4:10pm  Closing remarks

4:20pm  Reception

Speakers

Kurt Marek, PhD
Dr. Marek is the Deputy Director of the NHLBI Office of Translational Alliances and Coordination. He oversees NHLBI’s SBIR/STTR program that supports small businesses performing research and development on innovative biomedical products, as well as facilitates partnerships between small businesses, investors, and strategic partners.

Chris Sasiela, PhD, RAC
Dr. Sasiela is Regulatory Specialist in the NHLBI Office of Translational Alliances and Coordination. She provides consultative advice and develops regulatory affairs educational content for NHLBI small businesses, clinical investigators, and program staff, and facilitates communication between NHLBI investigators and the FDA.

Kathleen Rousche, PhD
Dr. Rousche is a Program Director in the NHLBI Office of Translational Alliances and Coordination. She oversees identification, planning, and development of new research initiatives that facilitate, catalyze, and enable the transition of technologies from bench to market. As part of this effort, Dr. Rousche manages the NIH Centers for Accelerated Innovations.

Roger Kitterman
Mr. Kitterman is Executive Director of the Boston Biomedical Innovation Center and Managing Partner of the Partners Innovation Fund. With 20 years of venture capital experience, he has guided multiple venture-backed companies through the earliest stages of development. Mr. Kitterman is also a founder of Mass Medical Angels, the only life science focused angel investment group in Boston.

Sheela Hedge
Sheela Hegde is a Partner and leader in Health Advances’ biopharma practice, helping companies maximize the value of their assets and build winning market positions. Experienced in multiple therapeutic areas, she has particular expertise in metabolic and autoimmune diseases. Sheela brings a cross-sector lens to her biopharma clients, providing strategic advice on integrated solutions and convergent products.
Panelists

Richard Anders, JD
Mr. Anders is Founder/Executive Director, Massachusetts Medical Angels and a long-time entrepreneur with a background in computers and life sciences. Mr. Anders also founded the angel group Launchpad, is a board observer at Avaxia Biologics and Sialix, and teaches medical device entrepreneurship at the Harvard/MIT HST program. Mr. Anders founded Jurisoft, which he sold to Lexis/Nexis; published newspapers including Boston Digital Industry and New York Digital Industry; and is currently managing director of Rubin/Anders Scientific, which places scientists as consultants in patent projects.

Barbara Fox, PhD
Dr. Fox is Founder and CEO of Avaxia Biologics, CEO, Inc., a company developing orally delivered antibody therapeutics designed to act locally in the gastrointestinal tract. Avaxia’s lead product is an orally delivered anti-TNF antibody being developed for both inflammatory bowel disease (Crohn’s disease and ulcerative colitis) and gastrointestinal acute radiation syndrome. Dr. Fox’s previous positions include Affiliated Entrepreneur at Oxford Bioscience Partners; Founder/President/Chief Scientific Officer of Recovery Pharmaceuticals; and Vice President, Immunology at ImmuLogic Pharmaceutical Corp.

Henry Kay
Mr. Kay is an active member of the angel groups Launchpad Venture and Boston Harbor Angels. He has 35 years of experience in the medical industry spanning R&D, international marketing, regulatory affairs, and strategic planning. Most recently and until his retirement in 2006, he held several senior positions at Boston Scientific Corporation. He also serves on the boards of several start-up health care companies in the United States and Canada, including Smart Cells (sold to Merck in 2010), Cool Systems, Cellaegis Devices, Prev Bio, Imagistx, and Cannuflow.

Reid Leonard, PhD
Dr. Leonard is Managing Director, MRL Ventures, the strategic venture capital group of Merck Research Laboratories that invests in early-stage therapeutics companies. Prior to joining MRL Ventures, Dr. Leonard spent 15 years in Merck Licensing & External Scientific Affairs, most recently as Executive Director, Scientific Search & Evaluation in Boston, Massachusetts. He started his Merck career as a discovery scientist working on structure and function of ion channels, cellular excitability, and membrane signaling in support of a variety of therapeutic programs.

Michael McGrail, JD
Mr. McGrail is a Partner in the Cooley Business department and a member of the firm's Mergers & Acquisitions, Medical Devices, Venture Capital Financings, and International Practice groups. Mr. McGrail counsels companies and investors in many industries, with a particular focus on medical devices and life sciences. He has also served as the Head of Regulatory Affairs at a German manufacturer of medical devices and as an associate in the Medical Device Practice at Hogan & Hartson in Washington, DC, with a focus on commercial, licensing and FDA regulatory issues.

Moderator: Stephen Flaim, PhD
Dr. Flaim is Special Advisor in the NHLBI Office of Translational Alliances and Coordination and Chairman, Tech Coast Angels. He is Founder and President of Flaim Partners Consulting and a board member of Pivotal Biosciences Inc. and AnaBios Corp. Dr. Flaim is Chairman of the Board for Leading Biosciences Inc., a technology and business adviser to the William J. von Liebig Center for Entrepreneurism and Technology Advancement at UC San Diego, Chairman of the Board of Directors for the John G. Watson Foundation, Cofounder/CEO of CardioCreate Inc., and Chairman/CEO of OncoFluor Inc.
Showcase Companies

Therapeutics

Progenra, Inc. is a biotechnology company based on therapeutic targets in the ubiquitin proteasome pathway. Core competencies include molecular biology, protein biochemistry, cell biology and biochemistry, assay development, high throughput screening, medicinal chemistry, and preclinical drug development. Progenra applies its proprietary assay technology to discover preclinical small molecule development candidates through internal programs or business collaborations. [Poster 2]

Pulmokine, Inc. is a biopharmaceutical company developing new treatments for pulmonary arterial hypertension (PAH). PAH is an orphan disease with high mortality with current treatment options, highlighting large unmet medical need. Pulmokine holds an exclusive license from Gilead for a patent portfolio of small molecule kinase inhibitors targeting the platelet-derived growth factor receptor to treat PAH. [Poster 4]

DeclImmune Therapeutics expects to enter the clinic in 2015 with its anti-N2 humanized monoclonal antibody for ischemic disease. Based on success in murine and porcine model systems, the first clinical target is the preservation of left ventricular function post-myocardial infarction. DeclImmune is exploring clinical opportunities using model systems such as vaso-occlusive crisis in sickle cell disease and ischemic renal disease. [Poster 1]

TheraSource, LLC is an early-stage biotech company that develops novel anti-inflammatory therapeutic agents, such as recombinant proteins, peptides, and small molecule compounds. TheraSource has both completed and ongoing preclinical studies of several drug candidates for various human diseases related to inflammation, including sepsis, hemorrhagic shock, stroke, acute radiation syndrome, ischemic organ injury, inflammatory bowel disease, and rheumatoid arthritis. [Poster 5]

Prolong Pharmaceuticals, LLC employs its proprietary PPBD™ technology platform to develop innovative molecules for treating the comorbidities of anemia, cancer, and other life-threatening diseases. Prolong's lead product, SANGUINATE™, is an intravenous therapeutic in clinical testing, focused on treating comorbidities of sickle cell disease and other disorders caused by ischemia, hypoxia, and/or hemolysis. [Poster 3]

Biomedica Management Corporation develops novel treatments in coagulopathy-related conditions with civilian and military applications, such as wound healing, fluid resuscitation, and sepsis. Its leading technology, the CLOT portfolio, represents next-generation hemostatic agents and sealants. Expected applications include treatments for non-compressible and high-volume hemorrhage during trauma as well as easy-to-use applications in ophthalmology, orthopedic, cardiac, gynecology, and general surgery. [Poster 6]

GLSynthesis, Inc. is a drug discovery company focusing on antibacterial and antithrombotic drugs. GLSynthesis has a broad-based business model and 18 years of experience, coupled with the large and expanding market for targeted therapies. [Poster 7]

Nanometrics, LLC focuses on developing novel therapeutics for diseases with high unmet medical need. Current research efforts are focused on late-stage preclinical development of small molecule therapeutics for triple-negative breast cancer and sickle cell disease. [Poster 8]
Showcase Companies

**Phoenicia BioSciences** is a therapeutics company that has developed therapeutic candidates for treating hemoglobin disorders, viral-associated lymphomas, refractory wounds associated with hemolytic anemias, and hematologic deficiencies after chemotherapy or radiation. [Poster 9]

**Aphios Corporation** is a clinical-stage biotechnology company that has developed eco-friendly enabling technology platforms for improving drug discovery, manufacturing, and nanotechnology drug delivery. We have also developed and patented a generally applicable pathogen-inactivation enabling technology platform, called CFI™, for preparing virus-free human plasma, biologics, and viral vaccines. [Poster 14]

**BlenderHouse** is a medical device and software-services company that aims to realize the potential of data to improve healthcare, from basic research to routine patient care. Blenderhouse is beta-testing a clinical decision-support application for end-stage heart failure. The software builds upon existing machine learning and data-mining technology. [Poster 15]

**CPSI Biotech** is a technology company that focuses on the modulation of cell stress as a central theme to develop novel medical devices and cell-processing consumables for the tissue ablation market. [Poster 16]

**Thermedical** develops innovative thermal therapies for cardiac arrhythmias and solid tumors. Thermedical has developed SERF® Ablation, a new form of thermal ablation that can create much larger therapy zones than competing approaches. This catheter-based system is uniquely capable of efficiently curing ventricular tachycardia (VT), using a disruptive technology that will eventually displace implantable cardioverter defibrillators (ICDs) from the VT market. [Poster 13]

**Giner, Inc.** is a medical device company performing applied research and development in electrochemistry and related areas, specifically developing innovative devices for the preservation of human organs, tissues, and cells. Giner’s two key products are a whole-organ oxygenator, currently in a clinical trial in Canada, and a miniature, implantable cell-capsule oxygenator, currently in a small-animal proof of concept study. [Poster 11]

**PinMed, Inc.** is a bioinformatics/medical-device company with a cloud-based, mobile monitoring platform (cleared by the FDA) and analytical software for the accurate tracking and early detection of subtle but clinically important changes in real-life longitudinal data. This platform provides an efficient tool for monitoring and analyzing the progress of clinical studies, improving efficiency and cutting the time and cost of product development and testing. [Poster 12]

**DVX, LLC** is focused on the development of new ultrasound devices that measure blood flow. Employing proprietary technology, its blood flow measuring devices are small, light, and low-cost. Featured at this conference is a “smart” vascular graft that monitors its own performance and wirelessly communicates its status. [Poster 10]
Showcase Companies

Devices (cont’d)

Mirtech, Inc. specializes in scientific research consultation and collaboration primarily in the field of NMR and MRI, with extensive experience in performing MRI research. Mirtech has extensive experience in the manufacture of custom MRI detectors for multi-nuclear operation as well as the design, construction, and implementation of MRI-safe devices to be used within the MRI suite. [Poster 18]

Diagnostics

Allied Innovative Systems - ALLIS is a biotechnology company with a portfolio of immunoassay and instrumentation products at different stages of development — from concept and licensing to sells. The ALLIS business model entails conceptual design and development followed by sequential licensing and manufacturing of novel instrumentation, diagnostic assays, reagents, and kits. [Poster 20]

Collagen Medical is a preclinical stage specialty pharmaceutical company that develops targeted molecular probes for medical imaging. Currently, we focus on two different technology platforms that target collagen and fibrin. [Poster 21]

Stay connected with NHLBI

www.nhlbi.nih.gov/about/dera/otac
(301) 496-2149
@NHLBI_SBIR

Bio International Convention
June 23-26 San Diego, CA
AdvaMed MedTech Conference
October 6-8 Chicago, IL
NHLBI Regional Innovation Conference
Fall 2014 San Francisco, CA

The NHLBI Office of Translational Alliances and Coordination
The Office of Translational Alliances and Coordination (OTAC) helps to move basic discoveries from laboratory to market to improve health. OTAC does this by providing leadership for the NHLBI small business program and developing trans-NIH SBIR/STTR funding opportunities, supporting universities’ efforts to create new technology development models, providing expert regulatory and commercialization advice to the NHLBI community, and developing strategic partnerships.

The National Heart, Lung, and Blood Institute
The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.

The National Institutes of Health
The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.